RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 142 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,517 | -16.3% | 1,405 | 0.0% | 0.00% | – |
| Q2 2023 | $1,812 | -2.3% | 1,405 | 0.0% | 0.00% | – |
| Q1 2023 | $1,855 | -7.2% | 1,405 | 0.0% | 0.00% | – |
| Q4 2022 | $2,000 | 0.0% | 1,405 | 0.0% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 1,405 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | -50.0% | 1,405 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | 0.0% | 1,405 | 0.0% | 0.00% | – |
| Q4 2021 | $4,000 | -20.0% | 1,405 | -6.6% | 0.00% | – |
| Q3 2021 | $5,000 | -16.7% | 1,505 | +7.1% | 0.00% | – |
| Q2 2021 | $6,000 | +20.0% | 1,405 | 0.0% | 0.00% | – |
| Q1 2021 | $5,000 | 0.0% | 1,405 | 0.0% | 0.00% | – |
| Q4 2020 | $5,000 | -79.2% | 1,405 | -86.5% | 0.00% | – |
| Q3 2020 | $24,000 | +9.1% | 10,405 | -12.6% | 0.00% | – |
| Q2 2020 | $22,000 | +144.4% | 11,905 | +104.1% | 0.00% | – |
| Q1 2020 | $9,000 | – | 5,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |